Overall verdict
Neutral
5.7/10
1-year performance
-1.70%
Score breakdown
Down 1.7% over 1 year, 87% of the 52-week range.
Strongest: Shareholder return 9.2/10. Weakest: Growth 4.4/10.
24 analysts, target +0.1% vs the price.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine.
It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform ;
Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases ; Nurix Therapeutics, Inc. to develop protein degradation therapies ; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis ; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies ;
Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease ; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab ; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Euronext
France
CEO
Belen Garijo Lopez
Founded
1994
Employees
76 493
Revenue / employee
586 532 EUR
Next earnings
January 28, 2027 (Q4 2026)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
90.79 EUR
52-week low
69.75 EUR
1-year performance
-1.70%
Declining
Year-to-date performance
6.26%
Declining
Drawdown
-3.10%
Near its high
Position in the 52-week range
87% of range
Against the world ETF
Over 25 years, from December 2001 to October 2026, the share did clearly worse than the world ETF once risk is accounted for. It earned less, while shaking 1.4 times harder.
10 000 € placed at the end of December 2001 are worth today
| Sanofi | 9 516 € |
| World ETF | 59 561 € |
| CAC 40 | 35 276 € |
| Risk-free placement | 14 262 € |
The risk
- Shaking:the share moves 1.4 times as much as the world ETF.
- Worst fall:-51 % between December 2001 and February 2009. 10 000 € placed at the top fell to 4 882 €. The world ETF, at worst: -49 %. Back to its high in 67 months.
Sanofi earned less than the world ETF since 2001
Value of 10 000 € placed at the end of December 2001, dividends reinvested, in euros
- Sanofi: 9 516 €
- World ETF: 59 561 €
- CAC 40: 35 276 €
- Risk-free placement: 14 262 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 78.49 EUR - 215.50 EUR (comparables only)
The price implies growth of -3.93% per year; the company grows at -10.00%.
Gross margin 66.3%, net margin 8.6%, ROIC 4.6%, ROE 5.7%.
Net margin
8.59%
Fair
Sector 9.99%|S&P 13.40%
Gross margin
66.29%
High
Return on equity (ROE)
5.66%
Fair
Sector 6.74%|S&P 17.06%
Return on invested capital (ROIC)
4.63%
Fair
Free cash flow margin (FCF)
22.25%
Exceptional
Profit-to-cash conversion (FCF conversion)
2.59x
Exceptional
Margin stability
2.9 pts
Steady
Revenue to net income
Growth
4.4/10Revenue up 15.7% over 1 year, 3.9% a year over 5, EPS -15.3% a year over 5.
Revenue (trailing 12 months)
45.8Md EUR
Revenue growth (1y)
15.70%
Hyper-growth
Revenue growth (3y)
1.46%
Moderate
EPS growth (1y)
43.91%
Strong
EPS CAGR (5y)
-15.33%
Declining
EPS revisions (3 months)
3.62%
Revised up
Valuation
5.2/10P/E 26.4x, forward P/E 13.9x, EV/EBITDA 6.3x, PEG 2.81. The multiple sits in the 30th percentile of its own 5-year history.
P/E (TTM)
26.4x
Fair
Sector 27.8x|S&P 23.6x
Forward P/E
13.9x
Fair
EV / EBITDA
6.3x
Cheap
Sector 14.3x|S&P 15.5x
PEG
2.81
Very expensive
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
147.00 EUR
Deeply undervalued
P/E vs its own 5-year history
among the 30% lowest valuations
Cheaper than usual
Market cap
104Md EUR
Financial strength
8.4/10Cash covers 26.9% of the debt, net debt/EBITDA 0.7x.
Net debt / EBITDA
0.7x
Solid
Gearing (net debt / equity)
24.76%
Very solid
Cash
6.2Md EUR
Cash / market cap
5.95%
Tight
Cash / total debt
26.93%
Tight
Interest coverage
11.3x
Very solid
Net debt
16.8Md EUR
Equity
67.6Md EUR
Closed daily candles, 2 years
Last close on November 11, 2026: 86.61 EUR
- MM2078.24
- MM5075.14
- MM20076.83
- RSI 1481.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.36%
200-day average slope, 3 months
-3.14%
50-day average slope, 1 month
+0.64%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
1.58 % per day
Volatility change
+5.70%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 6.35 (10) | 8.88 (20) | 48 913 (12) | 15 168 (13) | 7 676 (9) |
| 2027 | 7.51 (11) | 9.43 (21) | 51 532 (12) | 16 429 (14) | 9 238 (9) |
Amounts in millions of EUR, EPS in EUR per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 3 | ROP | 6.2 | 6.4 | 385Md USD | 26.2x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 4.7 % | 42.5 % | ||
| 4 | NOVN | 6.1 | 6.5 | 295Md USD | 32.0x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.0 % | 29.2 % | ||
| 5 | LLY | 6.0 | 5.1 | 1.4T USD | 47.2x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 48.7 % | ||
| 6 | SAN | 5.7 | 5.9 | 115Md USD | 26.4x | 8.6 % | 15.7 % | 4.6 % | 0.7x | 9.8 % | -1.7 % | ||
| 7 | JNJ | 5.6 | 5.2 | 675Md USD | 42.5x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.1 % | 48.1 % | ||
| 8 | MRK | 5.4 | 3.6 | 363Md USD | 150.3x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.1 % | 68.5 % | ||
| 9 | PFE | 5.2 | 4.6 | 168Md USD | 42.1x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.0 % | 20.3 % |
